Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Orthocell Ltd ( (AU:OCC) ) just unveiled an announcement.
Orthocell Limited has received regulatory approval to commence sales of its flagship nerve repair product, Remplir™, in Hong Kong, a strategically important market in the Asia Pacific region. This approval, granted ahead of schedule, adds to Orthocell’s growing portfolio of approvals in the US, Canada, Australia, New Zealand, Singapore, and Thailand, with further applications planned for the EU and UK. The company is leveraging external distributors to penetrate new markets while focusing internal resources on the US market. With a strong cash position and no debt, Orthocell is well-positioned to expand its commercial footprint and increase revenues.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company specializing in products for nerve repair surgery. Their primary product, Remplir™, is a collagen wrap used to assist surgeons in improving outcomes for damaged nerve repair and regeneration. The company is focused on expanding its market presence across Asia Pacific and North America, targeting a global addressable market estimated to be worth over US$3.5 billion.
Average Trading Volume: 1,640,903
Technical Sentiment Signal: Buy
Current Market Cap: A$333.9M
For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.